How a Drug Maker Profited by Slow-Walking a Promising H.I.V. Therapy; The New York Times, July 22, 2023

Rebecca Robbins and Sheryl Gay Stolberg, The New York Times; How a Drug Maker Profited by Slow-Walking a Promising H.I.V. Therapy

"Gilead, one of the world’s largest drugmakers, appeared to be embracing a well-worn industry tactic: gaming the U.S. patent system to protect lucrative monopolies on best-selling drugs...

Gilead ended up introducing a version of the new treatment in 2015, nearly a decade after it might have become available if the company had not paused development in 2004. Its patents now extend until at least 2031.

The delayed release of the new treatment is now the subject of state and federal lawsuits in which some 26,000 patients who took Gilead’s older H.I.V. drugs claim that the company unnecessarily exposed them to kidney and bone problems."

Cheaper TB drugs for millions after global deal on patent rights agreed; The Guardian, July 18, 2023

 Kaamil Ahmed, The Guardian ; Cheaper TB drugs for millions after global deal on patent rights agreed

"Pharmaceutical giant Johnson & Johnson has struck a deal to allow generic versions of its tuberculosis drug to be supplied to low-income countries – but the deal has been criticised for not going far enough to end the company’s monopoly on global supplies of bedaquiline.

The global patent of the drug ends on Tuesday 18 July, but in a number of countries Johnson & Johnson continues to control the market with secondary patents – for which small modifications are made to a product to extend a patent.

J&J’s decision will allow the Stop TB Partnership coalition to procure and supply generic bedaquiline to 44 low- and middle-income countries through its Global Drug Facility (GDF)."